Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma-Reference-Cited by-同舟云学术

Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma

Published:2009-08 Issue:3 Volume:146 Page:282-291
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Friedberg Jonathan W.,Kelly Jennifer L.,Neuberg Donna,Peterson Derick R.,Kutok Jeffery L.,Salloum Rabih,Brenn Thomas,Fisher David C.,Ronan Elizabeth,Dalton Virginia,Rich Lynn,Marquis Diana,Sims Paul,Rothberg Paul G.,Liesveld Jane,Fisher Richard I.,Coffman Robert,Mosmann Tim,Freedman Arnold S.

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2009.07773.x/fullpdf

Reference43 articles.

1. Pathogen recognition and innate immunity;Akira;Cell,2006

2. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients;Alvaro;Journal of Clinical Oncology,2006

3. B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny;Anolik;Clinical Immunology,2007

4. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma;Ansell;Blood,2002

5. Clinical and immunologic responses to a novel in situ lymphoma vaccine maneuver: results of a pphase II trial of intra-tumoral CpG (PF-3512676);Brody;Annals of Oncology,2008

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel insights into immune cells modulation of tumor resistance;Critical Reviews in Oncology/Hematology;2024-10

2. TLR9 agonism differentially impacts human NK cell-mediated direct killing and antibody-dependent cell-mediated cytotoxicity;Scientific Reports;2024-06-25

3. Safety and efficacy of parsaclisib in combination with rituximab, bendamustine + rituximab, or ibrutinib in patients with previously treated B-cell lymphoma: analysis of a phase 1 dose-finding study (CITADEL‑112);Leukemia & Lymphoma;2024-04-10

4. The role of Toll‐like receptors in neuropsychiatric disorders: Immunopathology, treatment, and management;Medicinal Research Reviews;2024-01-16

5. Toll-like receptor-guided therapeutic intervention of human cancers: molecular and immunological perspectives;Frontiers in Immunology;2023-09-26